Purity testing comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-08-27. Where a claim depends on a specific study, the study is described rather than over-claimed.
Nicotinamide adenine dinucleotide, commonly abbreviated NAD+, is a coenzyme present in all living cells. The molecule consists of two nucleotides linked by phosphate groups, with adenine and a nicotinamide ring as its principal features. In its oxidized form, the nicotinamide ring can accept a hydride ion, becoming NADH. This reversible conversion places NAD+ at the center of many electron-transfer reactions. Its role as a redox carrier is well established across bacteria, plants, fungi, and animals.
Beyond redox chemistry, NAD+ acts as a substrate for several enzyme families. ADP-ribosyltransferases, sirtuins, and CD38 ectoenzymes cleave the molecule into nicotinamide and ADP-ribose or related products. These reactions connect NAD+ availability to processes such as DNA repair, chromatin modification, and calcium signaling. Because the coenzyme is used in both electron transfer and signaling, cells maintain separate pools in compartments including the cytosol, mitochondria, and nucleus. The relative sizes and regulation of those pools remain active areas of study.
Cells produce NAD+ through several biosynthetic routes. The salvage pathway recycles nicotinamide, while the Preiss-Handler pathway uses nicotinic acid, and a de novo route can start from tryptophan in some organisms. In mammals, the salvage pathway is generally considered the main source under ordinary conditions. Tissue concentrations vary widely by cell type and compartment, and measured declines with age have been reported in some studies. Whether such changes drive aging or mainly accompany it remains an open question.
In cells, NAD+ functions primarily as an electron carrier. Dehydrogenase enzymes in glycolysis and the citric acid cycle transfer hydride from substrates to NAD+, producing NADH. NADH then delivers electrons to the mitochondrial respiratory chain, supporting ATP synthesis. In fermentation, NADH is reoxidized to NAD+ so that glycolysis can continue. The balance between NAD+ and NADH helps set metabolic flux. Beyond redox, NAD+ serves as a substrate for enzymes that cleave it, including sirtuins, poly(ADP-ribose) polymerases, and CD38. These reactions consume NAD+ and release nicotinamide and ADP-ribose products.
Biosynthesis occurs through salvage, Preiss-Handler, and de novo pathways. In mammals, the salvage pathway from nicotinamide predominates, and NAMPT is often described as rate-limiting. Nicotinamide riboside and nicotinic acid enter related routes that converge on NAD+ production. Tissue NAD+ concentrations vary widely and are maintained by a balance of synthesis and consumption. Some studies report age-related declines in certain tissues, but whether these changes cause disease or can be reversed to improve human health remains an open question.
| Property | Value | Notes |
|---|---|---|
| Chemical formula | C21H27N7O14P2 | Oxidized free acid form; charge depends on pH. |
| Molar mass | 663.43 g/mol | Calculated for the free acid. |
| CAS Registry Number | 53-84-9 | For the anhydrous free acid; salts have different identifiers. |
| Appearance | White to off-white powder | Solid material; hygroscopic. |
| Solubility | Water-soluble | Dissolves in aqueous buffers; solubility varies with pH and salt. |
Quality control for NAD+ materials typically combines identity, purity, and water content checks. Identity may be confirmed by ultraviolet spectrum, retention time in chromatography, or mass accuracy, while purity is assessed by HPLC peak area or quantitative nuclear magnetic resonance. Residual water and solvents can affect molar calculations and enzyme assays, so Karl Fischer titration or thermogravimetric analysis may be used. Commercial materials vary in grade and counterion form, and published methods should specify the exact salt or hydrate when reporting concentrations. Regulatory status depends on intended use, with research reagents, dietary ingredients, and clinical products treated under different frameworks.
Quantification of NAD+ in biological samples usually relies on separation techniques coupled to sensitive detection. High-performance liquid chromatography with ultraviolet detection can measure the oxidized form by its absorbance near 260 nm, while mass spectrometry provides greater specificity and can distinguish NAD+ from close analogs. Enzymatic cycling assays use coupled dehydrogenase reactions to amplify signal and estimate NAD+ concentrations in cell or tissue extracts. Because NAD+ and NADH interconvert rapidly, sample preparation must quench metabolism quickly and preserve the redox state before analysis.
The stability of NAD+ depends on pH, temperature, light exposure, and the presence of degradative enzymes. Aqueous solutions are generally more stable under mildly acidic to neutral conditions and degrade faster under alkaline conditions or prolonged heat. The solid is hygroscopic and should be stored desiccated, often frozen, and protected from repeated freeze-thaw cycles. In laboratory handling, aliquots reduce repeated temperature changes, and chelating agents may limit metal-catalyzed hydrolysis in some buffers. These practices matter because even small amounts of NADH or hydrolysis products can interfere with quantitative assays.
NAD+ is relatively unstable in aqueous solution, especially at neutral or alkaline pH and at elevated temperatures. It is typically stored dry, protected from light and moisture, and kept cold or frozen for long-term use. Solutions are often prepared fresh or buffered to mildly acidic pH to slow hydrolysis. Repeated freeze-thaw cycles can reduce integrity. Laboratories may verify concentration using ultraviolet absorbance at 259 nm or by enzymatic assay. These handling practices are general laboratory conventions rather than universal rules.
Research on NAD+ often examines changes with age, diet, exercise, and disease states, but causal relationships are difficult to establish. Some studies measure NAD+ levels, while others assess enzyme activity or downstream markers. In the literature, terms such as "NAD+ decline" and "NAD+ boosting" appear in both scientific and commercial contexts, sometimes without precise definitions. Whether changes in measured NAD+ directly produce health effects remains an open question. Results from cells, animals, and humans cannot be assumed to translate directly.
NAD+ is a dinucleotide composed of adenine, ribose, and nicotinamide moieties linked by phosphate groups. Its oxidized form carries a positive charge on the nicotinamide ring, which enables reversible hydride transfer. The molecule functions as a coenzyme in oxidoreductase reactions rather than as a dietary vitamin in its intact form. Cells maintain separate pools in cytoplasm, mitochondria, and nucleus. This compartmentalization allows distinct redox environments while preserving a shared chemical identity.
In glycolysis, NAD+ accepts electrons during the oxidation of glyceraldehyde-3-phosphate, forming NADH. The tricarboxylic acid cycle and fatty acid oxidation also generate NADH, which donates electrons to the mitochondrial electron transport chain. This flow supports ATP synthesis and helps maintain the redox balance of the cell. Other dehydrogenases use NAD+ as a cofactor for biosynthetic reductions and detoxification reactions. NADH is later reoxidized to sustain continued flux through these pathways.
== PEGylated drugs == The attachment of an inert and hydrophilic polymer was first reported around 1970 to extend blood life and control immunogenicity of proteins. Polyethylene glycol was chosen as the polymer. In 1981 Davis and Abuchowski founded Enzon, Inc., which brought three PEGylated drugs to market. Abuchowski later founded and is CEO of Prolong Pharmaceuticals. The clinical value of PEGylation is now well established. ADAGEN (pegademase bovine) manufactured by Enzon Pharmaceuticals, Inc., US was the first PEGylated protein approved by the U.S. Food and Drug Administration (FDA) in March 1990, to enter the market. It is used to treat a form of severe combined immunodeficiency syndrome (ADA-SCID), as an alternative to bone marrow transplantation and enzyme replacement by gene therapy. Since the introduction of ADAGEN, a large number of PEGylated protein and peptide pharmaceuticals have followed and many others are under clinical trial or under development stages. Sales of the two most successful products, Pegasys and Neulasta, exceeded $5 billion in 2011. All commercially available PEGylated pharmaceuticals contain methoxypoly(ethylene glycol) or mPEG. PEGylated pharmaceuticals on the market (in reverse chronology by FDA approval year) have included:
== External links == Molecular Dynamics Studio (2016) free open-source multi-scale modeling and simulation program for nano-composites with special support for structural DNA nanotechnology (originally Nanoengineer-1 by Nanorex) Nano-Hive: Nanospace Simulator (2006) free software for modeling nanotech entities Foresight Guidelines for Responsible Nanotechnology Development (2006) of molecular manufacturing technologies Center for Responsible Nanotechnology (2008) Molecular Assembler website (2008) Rage Against the (Green) Machine (2003) in Wired Government launches nano study UK EducationGuardian, 11 June 2003 Unraveling the Big Debate over Small Machines (2004) from BetterHumans.com Design considerations for an assembler (1995) by Ralph Merkle Kinematic Self-Replicating Machines — online technical book: first comprehensive survey of molecular assemblers (2004) by Robert Freitas and Ralph Merkle Design of a Primitive Nanofactory (2003) Video - Nanofactory in Action (2006) Nanofactory technology Review of Molecular Manufacturing Integrated Nanosystems for Atomically Precise Manufacturing — United States Department of Energy Workshop – August 5–6, 2015
== History == The corporate origins trace back to 1980, when the predecessor trading company (Ta Chiang International) was established. In the late 1990s the group created a biomedical division and moved progressively into health-care product development and manufacturing. In 2011 the company transitioned its business model from an ODM (original design manufacturer) to a CDMO (contract development and manufacturing organization), emphasizing integrated bioscience design, proprietary ingredient development and turnkey manufacturing services for clients seeking private-label and brand products. The firm went public on Taiwan's OTC market in 2013 (listing date 12 September 2013) with stock code 8436, accelerating capital access for factory expansion, R&D laboratories and overseas business development. Since the 2010s TCI has expanded into multiple subsidiaries and business lines (including genetic testing and digital health services), pursued international client partnerships, and invested in laboratory and production capacity—reporting a group workforce in the high hundreds and multiple manufacturing sites and laboratories by the early 2020s.
=== Detection === Quantification of alprazolam in blood and plasma samples may be necessary to confirm a diagnosis of intoxication in hospitalized patients, or to provide evidence in the case of crimes e.g., impaired driving arrest, or to assist in a thorough forensic investigation, e.g., in a medicolegal death investigation. Blood or plasma alprazolam concentrations are usually in a range of 10–100 μg/L in persons receiving the drug therapeutically, 100–300 μg/L in those arrested for impaired driving, and 300–2,000 μg/L in victims of acute overdosage. Most of the commercial immunoassays used for the benzodiazepine class of drugs cross-react with alprazolam, but confirmation and quantitative determination are usually done by chromatographic techniques.
Sources: en.wikipedia.org
== Further reading == He, Ran; Cao, Jie; Tan, Tieniu (2025). "Generative Artificial Intelligence: A Historical Perspective". National Science Review. 12 (5) nwaf050. doi:10.1093/nsr/nwaf050. PMC 11970245. PMID 40191253. James Gleick, "The Parrot in the Machine" (review of Emily M. Bender and Alex Hanna, The AI Con: How to Fight Big Tech's Hype and Create the Future We Want, Harper, 274 pp.; and James Boyle, The Line: AI and the Future of Personhood, MIT Press, 326 pp.), The New York Review of Books, vol. LXXII, no. 12 (24 July 2025), pp. 43–46. "[C]hatbox 'writing' has a bland, regurgitated quality. Textures are flattened, sharp edges are sanded. No chatbox could ever have said that April is the cruelest month or that fog comes on little cat feet (though they might now, because one of their chief skills is plagiarism). And when synthetically extruded text turns out wrong, it can be comically wrong. When a movie fan asked Google whether a certain actor was in Heat, he received this 'AI Overview': 'No, Angelina Jolie is not in heat.'" (p. 44.)
The large intestine forms an arch starting at the cecum and ending at the rectum and anal canal. It also includes the appendix, which is attached to the cecum. Its length is about 1.5 m, and the area of the mucosa in an adult human is about 2 m2 (22 sq ft). The longest part of the large intestine is the colon whose main function is to absorb water and salts. The large intestine begins at the cecum, where the appendix is located. This is also the start of the colon as the ascending colon in the back wall of the abdomen. At the right colic flexure (hepatic flexure) (the flexed portion of the ascending and transverse colon) it runs across the abdomen in the transverse colon, passing below the diaphragm. At the left colic flexure (splenic flexure) the flexed portion of the transverse and descending colon, it descends down the left side of the abdomen. It reaches the sigmoid colon which is a loop of the colon closest to the rectum and continues to the rectum and anal canal.
Weakness, drowsiness, ataxia, hypotension, and paralysis of throat and limbs may appear in less than one hour after the bite. Without medical treatment, symptoms rapidly worsen and death can occur rapidly after a bite due to respiratory failure. An adult woman bitten by this species in northwestern Pakistan suffered severe neurotoxicity and died while en route to the closest hospital nearly 50 minutes after envenomation. Between 1979 and 1987, 136 confirmed bites were attributed to this species in the former Soviet Union. Of the 136, 121 received antivenom, and only four died. Of the 15 who did not receive antivenom, 11 died. This species is an abundant snake in northeastern Iran and is responsible for a very large number of snakebite mortalities. Antivenom is not as effective for envenomation by this species as it is for other Asiatic cobras within the same region, like the Indian cobra (Naja naja) and due to the dangerous toxicity of this species' venom, massive amounts of antivenom are often required for patients. As a result, a monovalent antivenom serum is being developed by the Razi Vaccine and Serum Research Institute in Iran. The untreated mortality rate for this species is 70–75%, which is the highest among all cobra species of the genus Naja.
== Aftermath == The recapture of Constantinople signalled the restoration of the Byzantine Empire, and on 15 August, the day of the Dormition of the Theotokos, Emperor Michael VIII entered the city in triumph and was crowned at the Hagia Sophia. The rights of the legitimate emperor, John IV Laskaris, for whom Palaiologos had been ostensibly ruling as a guardian, were brushed aside, and the boy subsequently was blinded and imprisoned.
Although many mechanisms have been proposed, no definite model accounts for the mechanisms of chronic arsenic poisoning. The prevailing events of toxicity and carcinogenicity might be quite tissue-specific. The current consensus on the mode of carcinogenesis is that it acts primarily as a tumor promoter. Its co-carcinogenicity has been demonstrated in several models. However, the finding of several studies that chronically arsenic-exposed Andean populations (as most extremely exposed to UV-light) do not develop skin cancer with chronic arsenic exposure, is puzzling.
Sources: en.wikipedia.org
NAD+ is a coenzyme found in living cells and is the oxidized form of nicotinamide adenine dinucleotide. It accepts electrons in redox reactions and also serves as a substrate for certain signaling and repair enzymes.
NAD+ becomes NADH when it accepts a hydride ion during oxidation-reduction reactions. NADH then donates electrons to other molecules, after which the carrier can return to the NAD+ form.
No, nicotinamide is a smaller molecule and a component of NAD+. Cells can use nicotinamide to rebuild NAD+ through the salvage pathway.
Nicotinamide adenine dinucleotide, with the plus sign indicating the oxidized form. It is a coenzyme present in all living cells. The reduced form is NADH.